Disclosed are (i) compounds of formula I, or pharmaceutically acceptable salts thereof; and (ii) lipidoid nanoparticles comprising compound of formula I or pharmaceutically acceptable salts thereof, as well as their use as vehicles for drug delivery across the blood-brain barrier.

Disclosed are (i) compounds of formula I, or pharmaceutically acceptable salts thereof; and (ii) lipidoid nanoparticles comprising compound of formula I or pharmaceutically acceptable salts thereof, as well as their use as vehicles for drug delivery across the blood-brain barrier.

Provided is process for the synthesis of at least one functionalized organic polysulfide.

Provided is process for the synthesis of at least one functionalized organic polysulfide.

Presented herein are methods for making, isolating, and purifying N-acetylcysteine amide, (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide, diNACA), intermediates and derivatives thereof comprising: alternatively contacting cystine with methanol and a chlorinating reagent to form an organic solution containing L-cystine dimethylester dihydrochloride; combining dried or undried L-cystine dimethylester dihydrochloride with a triethylamine, an acetic anhydride, and an acetonitrile to form a di-N-acetylcystine dimethylester; mixing dried di-N-acetylcystine dimethylester with ammonium hydroxide to form a di-N-acetylcystine amide (diNACA); and separating dried di-N-acetylcystine dimethylester into N-acetylcysteine amide with dithiothreitol, triethylamine, and an alcohol.

Presented herein are methods for making, isolating, and purifying N-acetylcysteine amide, (2R,2R′)-3,3′-disulfanediyl bis(2-acetamidopropanamide, diNACA), intermediates and derivatives thereof comprising: alternatively contacting cystine with methanol and a chlorinating reagent to form an organic solution containing L-cystine dimethylester dihydrochloride; combining dried or undried L-cystine dimethylester dihydrochloride with a triethylamine, an acetic anhydride, and an acetonitrile to form a di-N-acetylcystine dimethylester; mixing dried di-N-acetylcystine dimethylester with ammonium hydroxide to form a di-N-acetylcystine amide (diNACA); and separating dried di-N-acetylcystine dimethylester into N-acetylcysteine amide with dithiothreitol, triethylamine, and an alcohol.

Disclosed herein, inter alia, are depalmitoylating compounds, compositions, and methods of use thereof.

Disclosed is a method for producing a trisulfide compound or a selenotrisulfide compound. This production method includes: a step for oxidizing a disulfide compound with an oxidizing agent to obtain a sulfoxide compound; and a step for reacting the sulfoxide compound that has been obtained with a source of sulfur or a source of selenium to obtain a trisulfide compound or a selenotrisulfide compound.

Disclosed is a method for producing a trisulfide compound or a selenotrisulfide compound. This production method includes: a step for oxidizing a disulfide compound with an oxidizing agent to obtain a sulfoxide compound; and a step for reacting the sulfoxide compound that has been obtained with a source of sulfur or a source of selenium to obtain a trisulfide compound or a selenotrisulfide compound.

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.